Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures
Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, announced the closing of a $40M Series A financing round.